Literature DB >> 23554313

NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand.

Gianfranco Pittari1, Xiao-Rong Liu, Annamalai Selvakumar, Zeguo Zhao, Ernesto Merino, Morgan Huse, Joseph H Chewning, Katharine C Hsu, Bo Dupont.   

Abstract

NK cells are regulated by inhibiting and activating cell surface receptors. Most inhibitory receptors recognize MHC class I Ags and protect healthy cells from NK cell-mediated autoaggression. However, certain activating receptors, including the human activating killer cell Ig-like receptor (KIR) 2DS1, also recognize MHC class I. This fact raises the question of how NK cells expressing such activating receptors are tolerized to host tissues. We investigated whether the presence of HLA-C2, the cognate ligand for 2DS1, induces tolerance in 2DS1-expressing NK cells. Anti-HLA-C2 activity could be detected in vitro in some 2DS1 positive NK clones irrespective of the presence or absence of HLA-C2 ligand in the donor. The frequency of anti-HLA-C2 reactivity was high in donors homozygous for HLA-C1. Surprisingly, no significant difference was seen in the frequency of anti-HLA-C2 cytotoxicity in donors heterozygous for HLA-C2 and donors without HLA-C2 ligand. However, donors homozygous for HLA-C2, compared with all other donors, had significantly reduced frequency of anti-HLA-C2 reactive clones. The 2DS1 positive clones that express inhibitory KIR for self-HLA class I were commonly noncytotoxic, and anti-HLA-C2 cytotoxicity was nearly exclusively restricted to 2DS1 single positive clones lacking inhibitory KIR. 2DS1 single positive NK clones with anti-HLA-C2 reactivity were also present posttransplantation in HLA-C2 positive recipients of hematopoietic stem cell transplants from 2DS1 positive donors. These results demonstrate that many NK cells with anti-HLA-C2 reactivity are present in HLA-C1 homozygous and heterozygous donors with 2DS1. In contrast, 2DS1 positive clones from HLA-C2 homozygous donors are frequently tolerant to HLA-C2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23554313      PMCID: PMC3643210          DOI: 10.4049/jimmunol.1202120

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets.

Authors:  Katharine C Hsu; Xiao-Rong Liu; Annamalai Selvakumar; Eric Mickelson; Richard J O'Reilly; Bo Dupont
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

3.  Predominant autoantibody production by early human B cell precursors.

Authors:  Hedda Wardemann; Sergey Yurasov; Anne Schaefer; James W Young; Eric Meffre; Michel C Nussenzweig
Journal:  Science       Date:  2003-08-14       Impact factor: 47.728

4.  Licensing of natural killer cells by host major histocompatibility complex class I molecules.

Authors:  Sungjin Kim; Jennifer Poursine-Laurent; Steven M Truscott; Lonnie Lybarger; Yun-Jeong Song; Liping Yang; Anthony R French; John B Sunwoo; Suzanne Lemieux; Ted H Hansen; Wayne M Yokoyama
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

5.  Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.

Authors:  Kouetsu Ogasawara; Jonathan Benjamin; Rayna Takaki; Joseph H Phillips; Lewis L Lanier
Journal:  Nat Immunol       Date:  2005-08-07       Impact factor: 25.606

6.  Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.

Authors:  Katrin Wiemann; Hans-Willi Mittrücker; Ute Feger; Stefan A Welte; Wayne M Yokoyama; Thomas Spies; Hans-Georg Rammensee; Alexander Steinle
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

7.  Tolerance and alloreactivity of the Ly49D subset of murine NK cells.

Authors:  T C George; J R Ortaldo; S Lemieux; V Kumar; M Bennett
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

8.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Authors:  Katharine C Hsu; Carolyn A Keever-Taylor; Andrew Wilton; Clara Pinto; Glenn Heller; Knarik Arkun; Richard J O'Reilly; Mary M Horowitz; Bo Dupont
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

9.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

10.  NK cell tolerance in mixed allogeneic chimeras.

Authors:  Yong Zhao; Hideki Ohdan; Jennifer O Manilay; Megan Sykes
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

View more
  34 in total

1.  Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Authors:  Wei Wang; Amy K Erbe; Kory A Alderson; Emily Phillips; Mikayla Gallenberger; Jacek Gan; Dario Campana; Jacquelyn A Hank; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-07-08       Impact factor: 6.968

2.  Activating Receptors for Self-MHC Class I Enhance Effector Functions and Memory Differentiation of NK Cells during Mouse Cytomegalovirus Infection.

Authors:  Tsukasa Nabekura; Lewis L Lanier
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

3.  A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.

Authors:  K Czaja; A-S Borer; L Schmied; G Terszowski; M Stern; A Gonzalez
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

Review 4.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I.

Authors:  Jeanette E Boudreau; Xiao-Rong Liu; Zeguo Zhao; Aaron Zhang; Leonard D Shultz; Dale L Greiner; Bo Dupont; Katharine C Hsu
Journal:  Immunity       Date:  2016-08-02       Impact factor: 31.745

6.  Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation.

Authors:  Hisayuki Yokoyama; Junya Kanda; Yuta Kawahara; Naoyuki Uchida; Masatsugu Tanaka; Satoshi Takahashi; Makoto Onizuka; Yuma Noguchi; Yukiyasu Ozawa; Yuna Katsuoka; Shuichi Ota; Takanori Ohta; Takafumi Kimura; Yoshinobu Kanda; Tatsuo Ichinohe; Yoshiko Atsuta; Hideki Nakasone; Satoko Morishima
Journal:  Bone Marrow Transplant       Date:  2021-01-08       Impact factor: 5.483

7.  Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.

Authors:  Ronald M Sobecks; Tao Wang; Medhat Askar; Meighan M Gallagher; Michael Haagenson; Stephen Spellman; Marcelo Fernandez-Vina; Karl-Johan Malmberg; Carlheinz Müller; Minoo Battiwalla; James Gajewski; Michael R Verneris; Olle Ringdén; Susana Marino; Stella Davies; Jason Dehn; Martin Bornhäuser; Yoshihiro Inamoto; Ann Woolfrey; Peter Shaw; Marilyn Pollack; Daniel Weisdorf; Jeffrey Milller; Carolyn Hurley; Stephanie J Lee; Katharine Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-08       Impact factor: 5.742

Review 8.  Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Trends Immunol       Date:  2018-01-31       Impact factor: 16.687

9.  Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation.

Authors:  Shiqiu Xiong; Andrew M Sharkey; Philippa R Kennedy; Lucy Gardner; Lydia E Farrell; Olympe Chazara; Julien Bauer; Susan E Hiby; Francesco Colucci; Ashley Moffett
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

10.  KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients.

Authors:  Meixin Shen; Yeh-Ching Linn; Ee-Chee Ren
Journal:  Immunogenetics       Date:  2015-12-09       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.